Saturday, October 31, 2026

Aspen Group Stock Soars 23% In 5 Sessions: Is This The Start Of A Bull Run?

ViaNews Editorial Team

November 13, 2023

Aspen Group Stock Soars 23% In 5 Sessions: Is This The Start Of A Bull Run?

(VIANEWS) - Aspen Group Shares Increase 23.1% Over Five Sessions; NASDAQ Gains 2.05% Shares of Aspen Group (NASDAQ: ASPU) experienced an unexpectedly sharp surge on Monday, increasing by 23.1% over five trading sessions to close at EUR0.17 from its opening price of EUR0.14. Overall market gains were also notable; increasing 2.05% to EUR13,798.11. Aspen Group's recent performance has been marked by extreme volatility, with its stock shifting dramatically in both directions. Even after its recent upswing, shares remain 68.81% below their 52-week high of EUR0.55. Investors will closely track developments at Aspen Group and market conditions to gauge how it might fare going forward.

About Aspen Group

Aspen Group, Inc. is an education technology company offering online higher education services in the US. They offer bachelor's, master's, and doctoral degree programs in nursing and health sciences, business & technology, arts & sciences & education through Aspen University & United States University; at April 30 2022 they had 13,334 degree-seeking students registered. Established in 1987 and based out of New York City.

Yearly Analysis

According to available data, Aspen Group's stock (ASPN) is trading at EUR0.17 at present; which is much lower than its 52-week high of EUR0.55 but higher than its low of EUR0.03. Aspen Group anticipates experiencing negative sales growth of 16.4% this year and 16.2% in 2019. Due to Aspen Group's declining sales growth outlook and current stock price, potential investors should proceed with caution before investing. It should be remembered that stock prices can be affected by numerous factors and past performance is not always indicative of future results; investors should conduct further research before making their final investment decision.

Technical Analysis

Aspen Group (ASPG) has seen its stock price skyrocket recently, exceeding both the 50-day and 200-day moving averages by more than EUR0.15. This indicates a significant upswing in sentiment on the market for their stock. Recent trading volume of 6 is significantly greater than its average trading volume of 29,908, reflecting increased enthusiasm in this stock. Volatility for this stock has been positive in the last week, month, and quarter, with average intraday variations averaging 7.70%, 0.06%, and 7.03% respectively. The highest amplitude was 13.22% for last week, 7.24% for month and 7.03% for quarter. According to the stochastic oscillator, Aspen Group stock is currently considered oversold (=20), indicating it may be an ideal time for investors to purchase it. Overall, Aspen Group stock seems to be in an upward trajectory with high buying interest and minimal volatility. Investors may wish to consider purchasing it while it remains relatively cheap.

Quarter Analysis

Aspen Group's current sales growth is cause for serious concern, as their negative 24% and 29.3% growths for this and next quarters represent a significant drop in revenue that may be linked to factors like changing market demand, competition or internal issues. Quarter-on-quarter revenue growth has decreased by 22.5% year over year over the last twelve months, reaching 70.92M now. Although still significant, negative revenue growth rates indicate that revenue is decreasing and may hinder its ability to invest in new products, services, or expansion opportunities. Investors should carefully assess any information regarding negative growth. Conduct additional research on what factors contributed to it and review financial statements, competitive landscape and management team strategies in place for addressing any challenges related to negative growth. With negative growth trends emerging, it's imperative that companies assess their long-term potential and whether the current stock price reflects that growth accurately. Seek professional advice or conduct a detailed analysis before making any investment decisions.

Equity Analysis

Aspen Group's poor EPS and ROE results indicate it may not be performing optimally financially. An EPS loss would indicate it is losing money, raising concerns among potential investors. On the other hand, its ROE suggests it has not effectively used its equity to generate profits and produce returns. However, it is important to keep in mind that one period of negative ROE may not indicate a long-term trend; significant changes or investments could have occurred within a company in recent months that impacted profitability negatively. Potential investors should thoroughly research both past financial performance as well as potential growth prospects prior to making investment decisions.

More news about Aspen Group (ASPU).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com